Editas Medicine, Inc. (EDIT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 35M 70M 105M Q4 '17: 13.7M Q1 '18: 17M Q2 '18: 21.2M Q3 '18: 29.5M Q4 '18: 31.9M Q1 '19: 30.1M Q2 '19: 25M Q3 '19: 14.4M Q4 '19: 20.5M Q1 '20: 24.2M Q2 '20: 32.6M Q3 '20: 91.6M Q4 '20: 90.7M Q1 '21: 91.5M Q2 '21: 81.1M Q3 '21: 24.5M Q4 '21: 25.5M Q1 '22: 25.8M Q2 '22: 31.8M Q3 '22: 25.6M Q4 '22: 19.7M Q1 '23: 22.8M Q2 '23: 19.3M Q3 '23: 24.6M Q4 '23: 78.1M Q1 '24: 69.4M Q2 '24: 67M Q3 '24: 61.8M Q4 '24: 32.3M Q1 '25: 35.8M Q2 '25: 38.9M Q3 '25: 46.4M Q4 '25: 40.5M Q1 '26: 38.7M Q2 '26: 47M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-270M -180M -90M 0 90M 180M 270M Q3 '16: -70.6M Q4 '16: -97.2M Q1 '17: -110M Q2 '17: -116.9M Q3 '17: -122.5M Q4 '17: -119.9M Q1 '18: -120.9M Q2 '18: -134.4M Q3 '18: -123.9M Q4 '18: -113.7M Q1 '19: -113.4M Q2 '19: -109.4M Q3 '19: -127.8M Q4 '19: -140.9M Q1 '20: -156.3M Q2 '20: -152M Q3 '20: -108.4M Q4 '20: -134.8M Q1 '21: -145.1M Q2 '21: -169.2M Q3 '21: -217.4M Q4 '21: -193.1M Q1 '22: -187M Q2 '22: -185.8M Q3 '22: -204.1M Q4 '22: -225.9M Q1 '23: -226.2M Q2 '23: -216M Q3 '23: -208.7M Q4 '23: -169.2M Q1 '24: -185.2M Q2 '24: -213M Q3 '24: -228.5M Q4 '24: -251.2M Q1 '25: -260.3M Q2 '25: -240M Q3 '25: -198.8M Q4 '25: -160M Q1 '26: -108.8M Q2 '26: -75.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-270M -180M -90M 0 90M 180M 270M Q3 '16: -70.4M Q4 '16: -97.2M Q1 '17: -110.5M Q2 '17: -117.9M Q3 '17: -123.5M Q4 '17: -120.3M Q1 '18: -120.2M Q2 '18: -132.4M Q3 '18: -121.1M Q4 '18: -110M Q1 '19: -108.3M Q2 '19: -103.3M Q3 '19: -121M Q4 '19: -133.7M Q1 '20: -142.2M Q2 '20: -132M Q3 '20: -91.2M Q4 '20: -116M Q1 '21: -135M Q2 '21: -166.7M Q3 '21: -213.6M Q4 '21: -192.5M Q1 '22: -186.3M Q2 '22: -184.5M Q3 '22: -201.1M Q4 '22: -220.4M Q1 '23: -219M Q2 '23: -205.8M Q3 '23: -195.1M Q4 '23: -153.2M Q1 '24: -166.1M Q2 '24: -193.4M Q3 '24: -210.6M Q4 '24: -237.1M Q1 '25: -251.2M Q2 '25: -236.9M Q3 '25: -199.8M Q4 '25: -160.1M Q1 '26: -109M Q2 '26: -73.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-240M -160M -80M 0 80M 160M 240M Q3 '16: -44.6M Q4 '16: -50.2M Q1 '17: 29.2M Q2 '17: 12.9M Q3 '17: 2M Q4 '17: -9.4M Q1 '18: -101.7M Q2 '18: -92.2M Q3 '18: -72.1M Q4 '18: -45.7M Q1 '19: -52.2M Q2 '19: -61.3M Q3 '19: -80.4M Q4 '19: -40.7M Q1 '20: -65.8M Q2 '20: -70.8M Q3 '20: -98.7M Q4 '20: -179.8M Q1 '21: -175.2M Q2 '21: -183.3M Q3 '21: -169.3M Q4 '21: -163.8M Q1 '22: -163.6M Q2 '22: -162.4M Q3 '22: -169.7M Q4 '22: -177.3M Q1 '23: -163.9M Q2 '23: -164.8M Q3 '23: -152.2M Q4 '23: -132.2M Q1 '24: -146.3M Q2 '24: -164.6M Q3 '24: -181.8M Q4 '24: -210.3M Q1 '25: -208.2M Q2 '25: -201.4M Q3 '25: -179.6M Q4 '25: -165.2M Q1 '26: -140.5M Q2 '26: -119.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-240M -160M -80M 0 80M 160M 240M Q3 '16: -47.8M Q4 '16: -53.7M Q1 '17: 26M Q2 '17: 10.5M Q3 '17: -471K Q4 '17: -11.5M Q1 '18: -104.1M Q2 '18: -95.7M Q3 '18: -75.7M Q4 '18: -50.5M Q1 '19: -56.7M Q2 '19: -65.9M Q3 '19: -86.3M Q4 '19: -46.8M Q1 '20: -73.4M Q2 '20: -78.7M Q3 '20: -106.2M Q4 '20: -187M Q1 '21: -180.3M Q2 '21: -189.3M Q3 '21: -175.8M Q4 '21: -171.8M Q1 '22: -173.7M Q2 '22: -170.5M Q3 '22: -176M Q4 '22: -181.5M Q1 '23: -167.6M Q2 '23: -169.2M Q3 '23: -156.2M Q4 '23: -136.9M Q1 '24: -151M Q2 '24: -171.5M Q3 '24: -191.4M Q4 '24: -219.1M Q1 '25: -215.3M Q2 '25: -204.9M Q3 '25: -180.7M Q4 '25: -165.8M Q1 '26: -141.1M Q2 '26: -120.5M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q3 '19: 49.8M Q1 '20: 54.6M Q2 '20: 55.3M Q3 '20: 62.7M Q1 '21: 66M Q2 '21: 67.9M Q3 '21: 68.2M Q1 '22: 68.5M Q2 '22: 68.6M Q3 '22: 68.7M Q1 '23: 68.9M Q2 '23: 71.4M Q3 '23: 81.6M Q1 '24: 81.9M Q2 '24: 82.3M Q3 '24: 82.5M Q1 '25: 83.1M Q2 '25: 84.4M Q3 '25: 90.1M Q1 '26: 97.9M Q2 '26: 119.3M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q3 '16: -4.95 Q4 '16: -3.09 Q1 '17: -3.14 Q2 '17: -3.25 Q3 '17: -3.30 Q4 '17: -2.99 Q1 '18: -2.81 Q2 '18: -2.98 Q3 '18: -2.66 Q4 '18: -2.33 Q1 '19: -2.26 Q2 '19: -2.13 Q3 '19: -2.47 Q4 '19: -2.68 Q1 '20: -2.77 Q2 '20: -2.51 Q3 '20: -1.73 Q4 '20: -2.00 Q1 '21: -2.17 Q2 '21: -2.55 Q3 '21: -3.24 Q4 '21: -2.85 Q1 '22: -2.73 Q2 '22: -2.70 Q3 '22: -2.94 Q4 '22: -3.21 Q1 '23: -3.18 Q2 '23: -2.96 Q3 '23: -2.70 Q4 '23: -2.03 Q1 '24: -2.08 Q2 '24: -2.34 Q3 '24: -2.54 Q4 '24: -2.88 Q1 '25: -3.04 Q2 '25: -2.85 Q3 '25: -2.38 Q4 '25: -1.83 Q1 '26: -1.17 Q2 '26: -0.69 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.